Noradrenaline shortage — US supply status & alternatives

Noradrenaline

ATC C01CA03

🇦🇺 AUST R 316838 · Boucher & Muir Pty Ltd

In supply · Australia

WHO Essential Medicine

LevophedNorepinephrineNoradrenaline bitartrate

In supply · 🇦🇺 Australia · short in🇨🇦 CA🇺🇸 US🇧🇪 BE

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Noradrenaline
Brand names	Levophed, Norepinephrine, Noradrenaline bitartrate
ATC level 5	C01CA03
ATC level 4	C01CA
Therapeutic category	Cardiovascular — vasopressor
WHO Essential Medicine	Yes
Controlled substance	No
Marketing-authorisation holders	Boucher & Muir Pty Ltd, Medicianz Healthcare Pty Ltd, Hospira UK Limited, LABORATOIRE AGUETTANT +4 more
Registrations on file	28
Patient information leaflet (PIL)	Not on file
Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Global API supply base 🇺🇸 FDA Drug Master Files · active Type II

1 API manufacturer

Manufacturers with an active Type II Drug Master File — i.e. cleared to supply this active ingredient into the US market. A proxy for how concentrated the global manufacturing base is.

Very high concentration risk

Edmond Pharma Srl

Manufacturing countries: Italy · Source: FDA List of Drug Master Files

Verified timeline regulator events

🇨🇦 7 May 2026

high reported

🇺🇸 20 Mar 2026

high reported

🇺🇸 20 Mar 2026

high reported

🇧🇪 2 Mar 2026

medium reported

🇧🇪 26 Sept 2025

medium reported

🇧🇪 26 Sept 2025

medium reported

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders28 registrations · 8 MA holders

Product	Strength	Form	Market	MA holder	Status
NORALIN Noradrenaline	3 mg	—	🇦🇺 AU	Boucher & Muir Pty Ltd	Active
NORALIN Noradrenaline	5 mg	—	🇦🇺 AU	Boucher & Muir Pty Ltd	Active
NORALIN Noradrenaline	6 mg	—	🇦🇺 AU	Boucher & Muir Pty Ltd	Active
NORALIN Noradrenaline	10 mg	—	🇦🇺 AU	Boucher & Muir Pty Ltd	Active
Medsurge	10 mg	—	🇦🇺 AU	Medicianz Healthcare Pty Ltd	Active
Medicianz	5 mg	—	🇦🇺 AU	Medicianz Healthcare Pty Ltd	Active
Medicianz	1 mg	—	🇦🇺 AU	Medicianz Healthcare Pty Ltd	Active
Medsurge	2 mg	—	🇦🇺 AU	Medicianz Healthcare Pty Ltd	Active
Medicianz	2 mg	—	🇦🇺 AU	Medicianz Healthcare Pty Ltd	Active
Medsurge	5 mg	—	🇦🇺 AU	Medicianz Healthcare Pty Ltd	Active
Mylan	4 mg	—	🇦🇺 AU	—	Active
Medicianz	10 mg	—	🇦🇺 AU	Medicianz Healthcare Pty Ltd	Active
Medsurge	1 mg	—	🇦🇺 AU	Medicianz Healthcare Pty Ltd	Active
Medicianz	8 mg	—	🇦🇺 AU	Medicianz Healthcare Pty Ltd	Active
Medicianz	4 mg	—	🇦🇺 AU	Medicianz Healthcare Pty Ltd	Active

+13 more registrations on file

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.